TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06436079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Patients who begin the first session in the hyperbaric chamber will receive a nursing educational intervention, with audiovisual support, about the operation of the chamber and aspects that must be taken into account once inside.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Patients who begin the first session in the hyperbaric chamber will receive a nursing educational intervention, with audiovisual support, about the operation of the chamber and aspects that must be taken into account once inside.
Study: NCT05209659

Intervention type: OTHER
Intervention: Pragmatic Mobilization
Description: The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.~Other Name: Non-thrust manipulation (pragmatically applied)
Study: NCT04831034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04
Description: Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
Study: NCT04839744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 produced by the modified manufacturing process
Description: Drug: TG103 (a modified manufacturing process), 15mg, SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TG103 produced by the original manufacturing process
Description: Drug: TG103 (the original manufacturing process), 15mg, SC
Study: NCT05827276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life story questionnaire
Description: Participant will receive physical therapy treatment as usual using information from Life Story Questionnaire.
Study: NCT04902781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-007
Description: Treatment with AT-007 given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given orally
Study: NCT04864743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW117
Description: a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW117
Description: a single dose.
Study: NCT06206512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release torsemide
Description: This is an extended-release formulation of torsemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release torsemide
Description: This is the generic, immediate release formulation of torsemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended release torsemide placebo
Description: Placebo of extended release torsemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release torsemide placebo
Description: Placebo of immediate release torsemide
Study: NCT04710212

Intervention type: OTHER
Intervention: No intervention.
Description: Observational study with no intervention.

Intervention type: OTHER
Intervention: No intervention.
Description: Observational study with no intervention.
Study: NCT05686655

Intervention type: OTHER
Intervention: questionnaire about sleep quality in diabetic children
Description: Pittsburgh sleep quality index
Study: NCT06044818

Intervention type: DEVICE
Intervention: Accexible
Description: Speech Analysis

Intervention type: DEVICE
Intervention: Accexible
Description: Speech Analysis
Study: NCT06139172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Behavioral Training (FBT)
Description: Function-based treatment (FBT) is a term for behavioral intervention approaches that use objective and systematic data collection to identify the cause of challenging behavior and teach a more prosocial replacement behavior. FBTslDD incorporates standard elements of FBT protocols with adaptations made specifically to support application to the syndromic IDD population. FBTslDD will include the following steps: (1) Syndromic IDD screening; (2) Stimulus preference assessment; (3) Indirect and descriptive assessments; (4) Screening for automatic function; (5) Functional analysis (FA); and (6) FBT intervention phase. If steps 1 - 5 determine a participant's challenging behavior serves a social function, Functional Communication Training (FCT) will be administered. If steps 1 - 5 determine a participant's challenging behavior serves an automatic function Competing Stimulus Treatment (CST) will be administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Parenting Strategies-Treatment as Usual
Description: Using the Planned Adaptation approach, to identify proactive adaptations seeking to improve the fit of FBTsIDD with the unique needs of the syndromic IDD population. Triangulating mixed methods data from systematic video observations, questionnaires, and qualitative interviews, then the Framework for Reporting Adaptations and Modifications-Expanded24 (FRAME) will be used to develop a rich understanding of these and any additional adaptations made to the intervention when delivered by non-specialist providers within medical hubs serving syndromic IDD populations.
Study: NCT05124522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MSPA eClass
Description: An 8-week MS-HAPA Internet-based intervention
Study: NCT05474183

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: drug
Study: NCT05656170

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Stellate ganglion block
Description: Ultrasound will be utilized to identify anatomic landmarks and prepare for the stellate ganglion block. Skin will be prepped with chloraprep. The C6 level is identified. The Chassaignac tubercle (the anterior tubercle of the C6 vertebral body) is then identified. Placement of the ultrasound transducer helps retract the carotid sheath and sternocleidomastoid muscle laterally. Pressure is applied with the ultrasound transducer to reduce the distance between the skin and tubercle.~The needle is inserted towards to the Chassaignac tubercle after contact it is redirected towards the body of C6. The needle is then withdrawn 1-2 mm to bring it out of the longus colli muscle while still staying within the prevertebral fascia. After negative aspiration, 1-2 mL of local anesthetic (or normal saline in the placebo group) is injected, and spread can be visualized with ultrasound. Once confirming that the injection was subfascial, the remaining local anesthetic can be given (10 mL in total).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Ultrasound will be utilized to identify anatomic landmarks and prepare for the stellate ganglion block. Skin will be prepped with chloraprep. The C6 level is identified. The Chassaignac tubercle (the anterior tubercle of the C6 vertebral body) is then identified. Placement of the ultrasound transducer helps retract the carotid sheath and sternocleidomastoid muscle laterally. Pressure is applied with the ultrasound transducer to reduce the distance between the skin and tubercle.~The needle is inserted towards to the Chassaignac tubercle after contact it is redirected towards the body of C6. The needle is then withdrawn 1-2 mm to bring it out of the longus colli muscle while still staying within the prevertebral fascia. After negative aspiration, 1-2 mL of local anesthetic (or normal saline in the placebo group) is injected, and spread can be visualized with ultrasound. Once confirming that the injection was subfascial, the remaining local anesthetic can be given (10 mL in total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: The intervention group will receive bupivacaine injection guided by ultrasound at the location of the stellate ganglion.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: The control group will receive a normal saline injection guided by ultrasound at the location of the stellate ganglion.
Study: NCT06527599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training - Maintenance (PCST-M)
Description: PCST-M consists of five weekly booster calls from the patient's study therapist to reinforce the techniques covered in the initial PCST-Lite session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training - Maintenance (PCST-M)
Description: PCST-M consists of five weekly booster calls from the patient's study therapist to reinforce the techniques covered in the initial PCST-Lite session.
Study: NCT02960737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral neuromuscular training using an oral device
Description: The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
Study: NCT06244576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behaviour Therapy (RO-DBT)
Description: RO-DBT is a trans diagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as anorexia nervosa, autism spectrum disorder, refractory depression, cluster c personality disorders, and mood disorders.
Study: NCT05672901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataMGT
Description: StrataMGT is a 100% medical grade film-forming silicone gel for the treatment of cutaneous skin lesions and Genitourinary Syndrome of Menopause. StrataMGT is a flexible wound dressing used on compromised skin. It dries to form a thin, flexible wound dressing which hydrates and protects affected areas. StrataMGT is used to relieve low grade inflammatory changes such as dry, itching, flaking, peeling and irritated skin. StrataMGT is designed for partially epithelized skin and is suitable for children and patients with sensitive skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrace 0.01% Vaginal Cream
Description: Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
Study: NCT05428995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC videolaryngoscope
Description: Patients with anticipated difficult airway will be awake intubated with a C-MAC videolaryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq videolaryngoscope.
Description: Patients with anticipated difficult airway will be awake intubated with a Airtraq videolaryngoscopy
Study: NCT04774653

Intervention type: OTHER
Intervention: No intervention
Description: Associations and prevalence will be calculated

Intervention type: OTHER
Intervention: No intervention
Description: Associations and prevalence will be calculated

Intervention type: OTHER
Intervention: No intervention
Description: Associations and prevalence will be calculated
Study: NCT05911373

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: group serratus plan block
Description: preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group serratus and parasternal plan block
Description: preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml %0.25 Bupivacaine
Study: NCT05247710

Intervention type: PROCEDURE
Intervention: Punch biopsy
Description: Punch biopsy of basal cell carcinoma tumor and a control biopsy of healthy skin are collected during primary tumor excision surgery from each recruited patient.
Study: NCT05265325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017 capsules TIW
Description: Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017 capsules QW
Description: Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
Description: Dose regimen and adjustment rules according to the USPI or SmPC or local practice
Study: NCT05538884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intertransverse process block
Description: The ITPB block at T5-6 will be performed with a mixture of local anesthetic with MRI contrast 0.5% bupivacaine 10 ml and 0.5 ml contrast in concentration 3.09 mmol/l. Volunteers will be moved to MRI machine and imaged in a supine position for their whole thoracic spine. This process will last about 45-60 minutes.
Study: NCT04911959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is taken orally.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE treatment once.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE treatment once.
Study: NCT05618314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: single dose AT-527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: single dose AT-527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: single dose AT-527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: Single dose of AT-527 pre- and post-dialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 and Probenecid
Description: Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
Study: NCT02870647

Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire
Description: each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
Study: NCT04549662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active A
Description: Powdered formula containing whey protein and arginine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active A
Description: Powdered formula containing whey protein and arginine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Active B
Description: Powdered formula containing whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid bolus
Description: Omega-3 fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Control placebo oil that does not contain omega-3 fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oil
Description: Control placebo oil that does not contain omega-3 fatty acids
Study: NCT06195436

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy for people with and without depression
Description: Participants with and without depression will be assigned to two study groups; both groups will undergo Acceptance and Commitment Therapy based on the required guidelines for twelve weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy for people with and without depression
Description: Participants with and without depression will be assigned to two study groups; both groups will undergo Acceptance and Commitment Therapy based on the required guidelines for twelve weeks.
Study: NCT06213558

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectangular and square striaght archwire technique
Description: The Effect of Rectangular Versus Square Archwire on Maxillary Canine Retraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectangular and square striaght archwire technique
Description: The Effect of Rectangular Versus Square Archwire on Maxillary Canine Retraction
Study: NCT04802499

Intervention type: PROCEDURE
Intervention: Turkish Reliability and Validity of TESS
Description: Translation and cultural adaptation of the scale will be designed according to the appropriate procedure. Turkish data will be uploaded in the online online method. The scale will be communicated online to those who have received telerehabilitation services, caregivers and healthcare professionals who have applied it. The reliability of the questionnaire will be made by test-retest and internal consistency analysis. Volunteers will be asked to answer the questionnaire online after 5 days. After two weeks, the participants will be asked to answer the questionnaire again with the same method online with 5 days intervals. After all data are collected, validity analysis will be performed

Intervention type: PROCEDURE
Intervention: Turkish Reliability and Validity of TESS
Description: Translation and cultural adaptation of the scale will be designed according to the appropriate procedure. Turkish data will be uploaded in the online online method. The scale will be communicated online to those who have received telerehabilitation services, caregivers and healthcare professionals who have applied it. The reliability of the questionnaire will be made by test-retest and internal consistency analysis. Volunteers will be asked to answer the questionnaire online after 5 days. After two weeks, the participants will be asked to answer the questionnaire again with the same method online with 5 days intervals. After all data are collected, validity analysis will be performed

Intervention type: PROCEDURE
Intervention: Turkish Reliability and Validity of TESS
Description: Translation and cultural adaptation of the scale will be designed according to the appropriate procedure. Turkish data will be uploaded in the online online method. The scale will be communicated online to those who have received telerehabilitation services, caregivers and healthcare professionals who have applied it. The reliability of the questionnaire will be made by test-retest and internal consistency analysis. Volunteers will be asked to answer the questionnaire online after 5 days. After two weeks, the participants will be asked to answer the questionnaire again with the same method online with 5 days intervals. After all data are collected, validity analysis will be performed
Study: NCT04806022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigability assessment
Description: Each participant will do both types of fatigue over 2 appointments spaced by 7 days so that the subject can recover from induced fatigue. The sequence of fatigue tasks will be randomized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigability assessment
Description: Each participant will do both types of fatigue over 2 appointments spaced by 7 days so that the subject can recover from induced fatigue. The sequence of fatigue tasks will be randomized.
Study: NCT05848037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cymactiv catheter device
Description: A new type of catheter has recently been submitted for CE marking as a Class IIb device and will soon be available in the UK market. Ingenion Medical's cymactive™ Catheter is designed to remain in situ for up to 30 days, does not extend outside the patient's body and has an integral, magnetically controlled valve that allows the user to control their own urination. The patient will be supplied with their own magnet so they are in control of valve and their own voiding. The magnet is strong and care will need to be taken to keep it at least 6 inches from magnetically-sensitive items.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley-type catheter device
Description: Routine standard of care
Study: NCT05104385

Intervention type: OTHER
Intervention: Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines
Description: Based on the Turkish Ministry of Health regulations, any research protocol involving use of any drug/vaccine needs to be presented in a clinical trial format, and is presented to the clinical research ethical boards accordingly. Otherwise, the study has no intervention (to the exposure status) involved. Selection, administration, number of doses applied and the period between vaccine doses are beyond the capacity the study team.
Study: NCT05758896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isuzinaxib (APX-115)
Description: Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
Study: NCT06434935

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CABA
Description: Coronary Bypass
Study: NCT06169462

Intervention type: PROCEDURE
Intervention: PENG block
Description: Patients underwent ultrasound-guided PENG Block for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.

Intervention type: PROCEDURE
Intervention: PENG block+ SIFCB
Description: Patients underwent ultrasound-guided PENG Block+ SIFCB for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
Study: NCT04939701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0739
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0739
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0739
Description: Intravenous (IV)
Study: NCT00013260

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Integrated model of primary care
Study: NCT06063928

Intervention type: PROCEDURE
Intervention: Archive Sample Retrieval
Description: Undergo collection of archival tumor tissue

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo stool and blood sample collection

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records reviewed

Intervention type: OTHER
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT04851106

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ultrasound
Description: Diagnosis of pancreatic adenocarcinoma with endoscopic ultrasound.